<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314079</url>
  </required_header>
  <id_info>
    <org_study_id>ANTG-ASC-203</org_study_id>
    <nct_id>NCT01314079</nct_id>
  </id_info>
  <brief_title>Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula</brief_title>
  <acronym>ANTG-ASC-203</acronym>
  <official_title>Follow-up Study to Evaluate the Sustained Efficacy and Safety for the Patients With Adipoplus Injected in Phase II Clinical Trials(ANTG-ASC-202)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open follow-up clinical trials to evaluate a sustained efficacy and safety of
      Adipoplus inj. for 10 months (12 months after final dose injection)after Phase II clinical
      trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Sustained efficacy of complete closure of fistula</measure>
    <time_frame>Month 4, 10</time_frame>
    <description>Proportion of patients whose fistula has been completely closed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with sustained efficacy of closure of fistula</measure>
    <time_frame>Month 2, 4, 10</time_frame>
    <description>Proportion of patients with more than 50% closed of fistula (Month 2, 4, 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with any adverse event</measure>
    <time_frame>Month 2, 4, 10</time_frame>
    <description>number of patients with any adverse event (Month 2, 4, 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of Investigator's satisfaction</measure>
    <time_frame>Month 2, 4, 10</time_frame>
    <description>Grade of Investigator's satisfaction (Month 2, 4, 10)
very satisfaction
satisfacttion
somewhat satisfaction
unsatisfaction
very unsatisfaction</description>
  </secondary_outcome>
  <enrollment type="Actual">37</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Fistula</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The patients who have participated in phase II clinical trial (ANTG-ASC-202) and injected
        with Adipoplus at least once.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the patients who have participated in ANTG-ASC-202 clinical trial

          -  the patients who have experienced with Adipoplus in ANTG-ASC-202 trials

          -  the patients who submit written consents and is able to obey requirements of trials

        Exclusion Criteria:

          -  pregnant or breast feeding

          -  autoimmune disease other than Crohn's disease

          -  infectious diseases including HBV, HCV or HIV

          -  who is not willing to use effective contraceptive methods during the study.

          -  active tuberculosis

          -  moderate to severe active or worsened Crohn's disease

          -  who have received Infliximab during or after ANTG-ASC-202 trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CS You, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaeHang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's fistula</keyword>
  <keyword>Autologous adipose derived stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

